Raul C. Ribeiro, MD: Advances in Pediatric Cancer
Dr. Raul Ribeiro talks about advances in pediatric cancer at St. Jude Children’s Research Hospital. In addition, he discusses the results of a phase one study — targeting the anaplastic lymphoma kinase (ALK) gene with the oral agent crizotinib (Xalkori) slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, anaplastic large cell lymphoma (ALCL), and inflammatory myofibroblastic tumors (IMTs).
This interview was filmed at the American Society of Clinical Oncology Annual Meeting in Chicago 2012.
Raul C. Ribeiro, MD has been a member of the St. Jude Children’s Research Hospital faculty for 23 years where he is currently the Director, Leukemia/Lymphoma Division and the Director, International Outreach Program.
The Group Room at the American Society of Clinical Oncology (ASCO) Annual Meeting 2012 was made possible, in part, by: